These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33681517)

  • 1. Raising Gene Therapy for Unmet Medical Needs in Japan.
    Ishii T
    JMA J; 2019 Mar; 2(1):73-79. PubMed ID: 33681517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan.
    Halioua-Haubold CL; Peyer JG; Smith JA; Arshad Z; Scholz M; Brindley DA; MacLaren RE
    Yale J Biol Med; 2017 Dec; 90(4):683-693. PubMed ID: 29259533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis and comparative evaluation of expedited programs for gene therapy products: insights from the United States, the European Union, Japan, and South Korea.
    Jeong H; Purja S; Kim E
    Gene Ther; 2024 May; 31(5-6):242-254. PubMed ID: 38200263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.
    Makita S; Imaizumi K; Kurosawa S; Tobinai K
    Drugs Context; 2019; 8():212567. PubMed ID: 30815024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
    Nagai S; Ozawa K
    Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personal imports of drugs to Japan in 2005--an analysis of import certificates.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2008 Oct; 33(5):545-52. PubMed ID: 18834370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of Japan's First Clinical Research Regulatory Law: Background, Overview, and Challenges.
    Akabayashi A; Nakazawa E; Akabayashi A
    HEC Forum; 2019 Dec; 31(4):283-294. PubMed ID: 31363880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase.
    Gupta S; Ahmad N; Mohan RR; Husain MM; Mukhtar H
    Cancer Res; 1999 May; 59(9):2115-20. PubMed ID: 10232597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.
    Köhl U; Arsenieva S; Holzinger A; Abken H
    Hum Gene Ther; 2018 May; 29(5):559-568. PubMed ID: 29620951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of chimeric antigen receptor T-cells in lymphoma.
    Anderson JK; Mehta A
    Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
    [No Abstract]   [Full Text] [Related]  

  • 15. Bleomycin--electrical pulse delivery: electroporation therapy-bleomycin--Genetronics; MedPulser-bleomycin--Genetronics.
    Drugs R D; 2004; 5(5):293-6. PubMed ID: 15357628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Jain T; Bar M; Kansagra AJ; Chong EA; Hashmi SK; Neelapu SS; Byrne M; Jacoby E; Lazaryan A; Jacobson CA; Ansell SM; Awan FT; Burns L; Bachanova V; Bollard CM; Carpenter PA; DiPersio JF; Hamadani M; Heslop HE; Hill JA; Komanduri KV; Kovitz CA; Lazarus HM; Serrette JM; Mohty M; Miklos D; Nagler A; Pavletic SZ; Savani BN; Schuster SJ; Kharfan-Dabaja MA; Perales MA; Lin Y
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2305-2321. PubMed ID: 31446199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychohistorical Hypotheses on Japan's History of Hostility Towards China.
    Wang B; Rudmin F
    J Psychohist; 2016; 44(1):24-40. PubMed ID: 27480012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Driving the CAR to the Bone Marrow Transplant Program.
    Dave H; Jerkins L; Hanley PJ; Bollard CM; Jacobsohn D
    Curr Hematol Malig Rep; 2019 Dec; 14(6):561-569. PubMed ID: 31643018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
    Lee YH; Kim CH
    Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.